Market Overview

UPDATE: Goldman Sachs Raises PT on Regeneron Pharmaceuticals Following Complete Phase 3 Eye Drug Data

Share:
Related REGN
The Drug Price Increase Debate: Separating The Winners From The Losers
Q2 Earnings Report Card: Biotech
Regeneron-Sanofi Could Beat Pfizer, Roche, AstraZeneca On Eczema (Investor's Business Daily)

In a report published Monday, Goldman Sachs analyst Terence Flynn reiterated a Buy rating on Regeneron Pharmaceuticals (NASDAQ: REGN), and raised the price target from $329.00 to $355.00.

In the report, Goldman Sachs noted, “REGN reported complete Phase 3 data for key eye drug, Eylea for a new indication (DME, vision loss due to diabetes) at the Retina Society conference. The data were in line with our expectations and we anticipate they will support approval for a broader label and drive uptake/growth.”

Regeneron Pharmaceuticals closed on Friday at $305.65.

Latest Ratings for REGN

DateFirmActionFromTo
Aug 2016BairdDowngradesOutperformNeutral
Jun 2016BernsteinInitiates Coverage onOutperform
Apr 2016Wells FargoDowngradesOutperformMarket Perform

View More Analyst Ratings for REGN
View the Latest Analyst Ratings

Posted-In: Goldman Sachs Terence FlynnAnalyst Color Price Target Analyst Ratings

 

Related Articles (REGN)

View Comments and Join the Discussion!